BR112021022335A2 - Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer - Google Patents

Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer

Info

Publication number
BR112021022335A2
BR112021022335A2 BR112021022335A BR112021022335A BR112021022335A2 BR 112021022335 A2 BR112021022335 A2 BR 112021022335A2 BR 112021022335 A BR112021022335 A BR 112021022335A BR 112021022335 A BR112021022335 A BR 112021022335A BR 112021022335 A2 BR112021022335 A2 BR 112021022335A2
Authority
BR
Brazil
Prior art keywords
morpholinopyridin
hydroxyethoxy
methylphenyl
isonicotinamide
trifluoromethyl
Prior art date
Application number
BR112021022335A
Other languages
English (en)
Inventor
Stephen Harlacher Cornelius
Murlidhar Waykole Liladhar
Zaixing Li
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112021022335A2 publication Critical patent/BR112021022335A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorometilisonicotinamida como inibidores raf para otratamento de cancer. a presente invenção refere-se a formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2-(trifluorometil) isonicotinamida e a processos para sua preparação. adicionalmente, a invenção refere-se a uma composição farmacêutica que compreende as ditas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida e pelo menos um excipiente farmaceuticamente aceitável. a composição farmacêutica da presente invenção pode ser usada como um medicamento, em particular para o tratamento de cânceres.
BR112021022335A 2019-05-13 2020-05-12 Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer BR112021022335A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019086595 2019-05-13
PCT/IB2020/054491 WO2020230028A1 (en) 2019-05-13 2020-05-12 New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112021022335A2 true BR112021022335A2 (pt) 2021-12-28

Family

ID=70740724

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022335A BR112021022335A2 (pt) 2019-05-13 2020-05-12 Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer

Country Status (13)

Country Link
US (1) US20220267299A1 (pt)
EP (1) EP3969449A1 (pt)
JP (1) JP2022531969A (pt)
KR (1) KR20220008273A (pt)
CN (1) CN113795490A (pt)
AU (1) AU2020276695A1 (pt)
BR (1) BR112021022335A2 (pt)
CA (1) CA3138123A1 (pt)
CL (1) CL2021002963A1 (pt)
IL (1) IL287030A (pt)
MX (1) MX2021013817A (pt)
TW (1) TW202108579A (pt)
WO (1) WO2020230028A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
JP2022517222A (ja) 2019-01-10 2022-03-07 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
JP2022546043A (ja) 2019-08-29 2022-11-02 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｄ阻害剤
CA3152025A1 (en) 2019-09-24 2021-04-01 David BRIERE Combination therapies
EP4076418A4 (en) 2019-12-20 2024-01-24 Mirati Therapeutics Inc SOS1 INHIBITORS
CN117425650A (zh) * 2021-06-04 2024-01-19 齐鲁制药有限公司 一种raf激酶抑制剂的晶型及其制备方法
WO2023108108A1 (en) * 2021-12-09 2023-06-15 Deciphera Pharmaceuticals, Llc Raf kinase inhibitors and methods of use thereof
WO2023166345A2 (en) 2022-03-02 2023-09-07 Novartis Ag Precision therapy for the treatment of cancer
WO2024033703A1 (en) 2022-08-10 2024-02-15 Novartis Ag Amorphous solid dispersions comprising naporafenib

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors

Also Published As

Publication number Publication date
EP3969449A1 (en) 2022-03-23
AU2020276695A1 (en) 2021-12-23
IL287030A (en) 2021-12-01
CN113795490A (zh) 2021-12-14
JP2022531969A (ja) 2022-07-12
TW202108579A (zh) 2021-03-01
KR20220008273A (ko) 2022-01-20
US20220267299A1 (en) 2022-08-25
MX2021013817A (es) 2021-12-14
CL2021002963A1 (es) 2022-09-09
WO2020230028A1 (en) 2020-11-19
CA3138123A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
BR112021022335A2 (pt) Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer
ECSP19044159A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
UY38221A (es) Inhibidores de proteínas ras con g12c mutantes
NI202000099A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
CR20170411A (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
DOP2016000071A (es) Inhibidores de tirosina cinasa de bruton
BRPI0612188B8 (pt) preparação farmacêutica para aplicação oral, método para a produção de uma preparação farmacêutica oral, preparação de comprimido para aplicação oral, método para a produção de uma preparação de comprimido
BR112013021537A2 (pt) derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
BRPI0720588B8 (pt) derivados de pirazol-quinazolina substituídos, processo para sua preparação e seu uso como inibidores da quinase
BR112022007612A2 (pt) Inibidores de raf quinases
AR108889A1 (es) Combinaciones para el tratamiento del cáncer
BR112015018168A2 (pt) inibidores de rock suaves
BR112018073951A2 (pt) forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
BR112016001544A2 (pt) composições farmacêuticas para injeção intraocular compreendendo agentes anti-bacteriano e anti-inflamatório, seu método de preparação, kit farmacêutico e uso dos referidos agentes no preparo das referidas composições farmacêuticas
BR112022008365A2 (pt) Inibidores de cd73
BR112021026820A2 (pt) Inibidores heterocíclicos de monoacilglicerol lipase (magl)
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
BR112023001861A2 (pt) Composições e métodos para tratamento de doenças e distúrbios